Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Clovis Oncology Inc (NQ: CLVS )

8.410 USD +0.200 (+2.44%)
Streaming Delayed Price Updated: 4:01 AM EST, Jan 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Clovis Oncology Inc

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. The financial information presented... 
From Business Wire News Releases
Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for... 
From Business Wire News Releases
Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?
InvestorsObserver issues critical PriceWatch Alerts for AGIO, CLVS, AQMS, COCP, and LAZR. 
From PR Newswire
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ova
Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed progression-free... 
From Business Wire News Releases
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.5 
From Business Wire News Releases
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference 
From Business Wire News Releases
Clovis Oncology Announces Third Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company’s clinical development programs and regulatory and... 
From Business Wire News Releases
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes 
From Business Wire News Releases
Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will... 
From Business Wire News Releases
Global Brain Tumor Therapeutics Market Projected to Exceed $2.70 Billion By 2023
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Brain Tumor Therapeutics Market Projected to Exceed $2.70 Billion By 2023
Financialnewsmedia.com News Commentary 
From PR Newswire
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline 
From Business Wire News Releases
Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting
Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting 
From Business Wire News Releases
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020 
From Business Wire News Releases
Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference 
From Business Wire News Releases
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, mCRPC 
From Business Wire News Releases
Clinical Trials Testing New Paradigms For Advanced Therapies Treating Metastatic Cancer Conditions
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Clinical Trials Testing New Paradigms For Advanced Therapies Treating Metastatic Cancer Conditions
Financialnewsmedia.com News Commentary 
From PR Newswire
Thinking about buying stock in NovaBay Pharmaceuticals, RISE Education, eMagin Corp, Avinger Inc, or Clovis Oncology?
InvestorsObserver issues critical PriceWatch Alerts for NBY, REDU, EMAN, AVGR, and CLVS. 
From PR Newswire
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
JCO Publishes Additional Data from CLVS TRITON2 Clinical Trial Evaluating Rubraca® for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations 
From Business Wire News Releases
Clovis Oncology Announces Second Quarter 2020 Operating Results
Clovis Oncology Announces Second Quarter 2020 Operating Results 
From Business Wire News Releases
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in ... 
From Business Wire News Releases
Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets. Clovis’ senior management will... 
From Business Wire News Releases
Why Developments for Targeted Therapies Are Expected to Drive Sales for Brain Tumor Drug Market
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Why Developments for Targeted Therapies Are Expected to Drive Sales for Brain Tumor Drug Market
Financialnewsmedia.com News Commentary 
From PR Newswire
Clinical Trials For New Therapies Providing Hope For Metastatic Breast Cancer Patients
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Clinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer Patients
Financialnewsmedia.com News Commentary 
From PR Newswire
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
- Combination Therapy Resulted in Durable, Dose-Dependent Antitumor Efficacy in a Preclinical Model of Colon Cancer - 
From PR Newswire
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020 
From Business Wire News Releases
Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca® (rucaparib),... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.